Lunit targets U.S. market, expanded AI portfolio with bid for Volpara

Continuing its aggressive push for global growth, South Korean artificial intelligence (AI) software developer Lunit has inked a deal to acquire breast and lung imaging AI software firm Volpara Health Technologies for approximately $292 million Australian dollars ($193 million U.S.). For Lunit, the acquisition would bring access to Volpara’s installed base in the U.S. market; Volpara’s mammography AI software is currently in use at over 2,000 U.S. sites, according to the vendors. In addition, Lunit hopes to utilize Volpara’s repository of over 100 million mammography images to develop new AI capabilities. “Combining Volpara’s established presence in the U.S. with Lunit’s complementing global footprint and AI expertise will create a compelling portfolio of advanced AI-enabled solutions for radiology and for other healthcare specialties," said Lunit CEO Brandon Suh in a statement. The deal follows on recent U.S. Food and Drug Administration (FDA) clearance for Lunit’s Insight DBT AI software for analysis of digital breast tomosynthesis (DBT) exams. Lunit’s CXR Triage software for triage of emergency x-ray cases garnered FDA clearance in November 2021. Lunit has been actively pursuing global expansion, including participation in Saudi Arabia’s Saudi Vision 2030 Healthcare Sandbox and forming a partnership to help develop Saudi Arabia’s national cancer screening program. It has also formed a collaboration with a Swedish hospital for use of its Insight MM...
Source: AuntMinnie.com Headlines - Category: Radiology Authors: Tags: Breast Artificial Intelligence M&A Breast Imaging Source Type: news